Daily PubMed evidence board
Prenatal exposure to asthma medications and risk of neurodevelopmental disorders and educational difficulties: A systematic review and meta-analysis
This systematic review and meta-analysis pooled studies that looked at whether taking asthma medicines before or during pregnancy is linked to later probl…
Signal score64Research triage score
CertaintyModerateVerify in full text
PMID42224295Source identifier
Research triage, not medical advice
Do not use this summary, score, or benefit-cost estimate to diagnose, treat, prescribe, or change care without reviewing the full study and consulting qualified professionals.
Verify before acting
Check full-text methods, eligibility, outcomes, risk of bias, harms, conflicts, funding, replication, and applicability.
Plain-English signal
This systematic review and meta-analysis pooled studies that looked at whether taking asthma medicines before or during pregnancy is linked to later problems with child development or school performance. The authors found inconsistent results across eight studies including cohorts and case-controls (about 3.87 million participants). In pooled analysis of three large studies (about 1.38 million), maternal use of beta-2-adrenergic agonists (a class of quick-acting asthma inhalers) was associated with higher odds of autism spectrum disorder both for exposure before conception (adjusted odds ratio 1.34) and during pregnancy (adjusted odds ratio 1.29). Results for ADHD were reported in only one study and need confirmation. The review notes important limitations: possible remaining confounding (for example, effects of the mother's underlying asthma rather than the medicine), exposure misclassification, and few studies in the pooled analyses. The authors did not find evidence linking these exposures to communication, motor, problem-solving or personal-social skills, or cerebral palsy based on the studies they identified.
Why it matters
- Addresses whether prenatal exposure to common asthma medications (beta-2-adrenergic agonists and inhaled corticosteroids) is associated with child neurodevelopmental disorders (ASD, ADHD) - a question directly relevant to antenatal prescribing decisions.
- Findings may influence risk-benefit discussions for pregnant people with asthma, balancing maternal risk from uncontrolled asthma against potential long-term child developmental risks.
- Large pooled sample sizes (millions in included cohorts) could meaningfully change risk estimates used in guidelines or patient counseling if associations are real and causal.
Primary outcomes
- Autism spectrum disorder (ASD)
- Attention-deficit hyperactivity disorder (ADHD)
- Other neurodevelopmental and educational outcomes (communication, motor skills, problem-solving, personal-social skills, cerebral palsy)
Effect summary
Meta-analysis of three studies (n ≈ 1,380,871) reported adjusted odds ratios for ASD with prenatal beta-2-adrenergic agonist (B2AA) exposure: preconception aOR 1.34 (95% CI 1.19-1.52) and during pregnancy aOR 1.29 (95% CI 1.16-1.42). Results for ADHD came from a single study and were not yet corroborated. Overall included studies reported inconsistent findings and were limited by potential residual confounding and exposure misclassification.
Benefit-cost lens
| Quick take | Meta-analysis suggests increased odds of autism spectrum disorder (ASD) associated with prenatal beta-2-adrenergic agonist (B2AA) exposure. Translating this to practice or policy requires absolute risks, costs, and consideration of harms from untreated maternal asthma. |
|---|---|
| BCR anchor | 2 |
| Time horizon | 3 |
| Discount rate | 0.03 |
| Assumptions | Assessment based solely on PubMed metadata and abstract; assumes reported adjusted odds ratios reflect pooled adjusted analyses but full-text verification is required to confirm covariates, exposure definitions, and potential overlapping populations. |
Benefit-cost fields are assumptions-based unless explicitly source-derived. Treat them as prompts for deeper economic review.
Risk of bias
| Tool | abstract-limited appraisal (Newcastle-Ottawa used in review as per abstract) |
|---|---|
| Verdict | Some concerns |
| Notes | Assessment based on the abstract: included studies were observational (cohort and case-control) and at risk of residual confounding (notably confounding by indication/severity of maternal asthma) and exposure misclassification. Meta-analysis included only three studies for key pooled estimates; full-text needed to evaluate study overlap, covariate adjustment, outcome ascertainment, and heterogeneity beyond Cochran's Q/I2 reported as low. |
Harms, equity, conflicts & implementation
| Implementation | Full-text review to confirm exposure definitions, timing, dose, confounder adjustment, and absolute risks; clinician and patient counseling frameworks; potential need for alternative asthma management protocols and safety monitoring; and health-economic inputs for cost-effectiveness. |
|---|---|
| Equity impact | Unclear from abstract. Potential equity concerns if medication access, asthma control, or diagnostic ascertainment for neurodevelopmental disorders differ by socioeconomic status or ethnicity; full-text and subgroup data needed. |
| Harms | Potential harms reported are indirect (association with ASD); the abstract notes residual confounding and misclassification. Harms from altering maternal asthma treatment (e.g., increased exacerbations) are not evaluated in this review and must be considered before changing practice. |
| Replication | Unknown from abstract-level triage; pooled analysis based on three studies with low heterogeneity per abstract but replication across diverse settings not established. |
Source links — verify original
Use PubMed and full-text links to confirm methods, population, outcomes, harms, conflicts, and applicability.